Tuesday 27 February 2018 by FIIG Research Company factsheets

Teva Pharmaceuticals Netherlands III B.V. USD 3.15% 1-Oct-26 Senior Unsecured Notes Factsheet


Teva Pharmaceuticals Netherlands III B.V. USD 3.15% 1-Oct-26 Senior Unsecured Notes Factsheet

Teva Pharmaceutical Finance Netherlands III B.V. (''Teva Finance''), is an indirect, wholly owned subsidiary of Teva Pharmaceutical Industries Limited ("Teva, Company") and has no assets or operations other than in connection with this offering.

Teva Pharmaceutical Industries Ltd. (Teva, Company) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.

Teva operates its business in two segments:
1. Generic medicines, which include chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Company is the leading generic drug company in the United States and Europe, and has a significant or growing presence in its Rest of the World markets. Teva is also one of the world's leading manufacturers of active pharmaceutical ingredients.

2. Specialty medicines, which include several franchises, most significantly the Company’s core therapeutic areas of central nervous system medicines such as Copaxone®, Azilect® and Nuvigil© and of respiratory medicines such as ProAir® HFA and QVAR®. Teva’s specialty medicines segment includes other therapeutic areas, such as oncology medicines, including Treanda®, women's health and selected other areas.

  • View the Teva Pharmaceuticals USD July 2023 Factsheet.External link - opens in a new window

Note: Access to the content will require a FIIG client login